Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
EXELIXIS, INC. | Director | Common Stock | 35.7K | $857K | $24.01 | Mar 21, 2024 | Direct |
VERTEX PHARMACEUTICALS INC / MA | Director | Stock Option (Right to Buy) | 3.14K | $256K | $81.54 | May 1, 2024 | Direct |
EXELIXIS, INC. | Director | Option (right to buy) | 0 | Mar 21, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
VRTX | VERTEX PHARMACEUTICALS INC / MA | May 1, 2024 | 1 | $0 | 4 | May 3, 2024 | Director |
EXEL | EXELIXIS, INC. | Mar 21, 2024 | 3 | -$1.39K | 4 | Mar 25, 2024 | Director |
EXEL | EXELIXIS, INC. | Jun 1, 2023 | 1 | $0 | 4 | Jun 2, 2023 | Director |
VRTX | VERTEX PHARMACEUTICALS INC / MA | May 1, 2023 | 2 | $0 | 4 | May 3, 2023 | Director |
EXEL | EXELIXIS, INC. | Feb 21, 2023 | 3 | -$448K | 4 | Feb 23, 2023 | Director |
EXEL | EXELIXIS, INC. | May 26, 2022 | 1 | $0 | 4 | May 27, 2022 | Director |
VRTX | VERTEX PHARMACEUTICALS INC / MA | May 1, 2022 | 1 | $0 | 4 | May 3, 2022 | Director |
EXEL | EXELIXIS, INC. | Mar 1, 2022 | 3 | -$322K | 4 | Mar 3, 2022 | Director |
EXEL | EXELIXIS, INC. | May 27, 2021 | 1 | $0 | 4 | May 28, 2021 | Director |